ATE104973T1 - (2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren. - Google Patents
(2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren.Info
- Publication number
- ATE104973T1 ATE104973T1 AT9090311021T AT90311021T ATE104973T1 AT E104973 T1 ATE104973 T1 AT E104973T1 AT 9090311021 T AT9090311021 T AT 9090311021T AT 90311021 T AT90311021 T AT 90311021T AT E104973 T1 ATE104973 T1 AT E104973T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- carbon atoms
- alkyl radicals
- radicals containing
- ylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/420,817 US5077292A (en) | 1989-10-12 | 1989-10-12 | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
EP90311021A EP0422878B1 (de) | 1989-10-12 | 1990-10-09 | (2-Imidazolin-2-ylamino)-tetrahydro-chinoxaline und Anwendungsverfahren |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE104973T1 true ATE104973T1 (de) | 1994-05-15 |
Family
ID=23667965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT9090311021T ATE104973T1 (de) | 1989-10-12 | 1990-10-09 | (2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren. |
Country Status (12)
Country | Link |
---|---|
US (2) | US5077292A (de) |
EP (1) | EP0422878B1 (de) |
JP (1) | JP2971118B2 (de) |
AT (1) | ATE104973T1 (de) |
AU (1) | AU628666B2 (de) |
CA (1) | CA2025212C (de) |
DE (1) | DE69008472T2 (de) |
DK (1) | DK0422878T3 (de) |
ES (1) | ES2063289T3 (de) |
HK (1) | HK1004266A1 (de) |
IE (1) | IE65784B1 (de) |
WO (1) | WO1992013855A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326763A (en) * | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5198442A (en) * | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5369128A (en) * | 1993-06-21 | 1994-11-29 | Iowa State University Research Foundation, Inc. | Method of synchronizing farrowing in swine |
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
CA2173974C (en) * | 1993-10-13 | 2006-05-02 | James A. Burke | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
JPH09506622A (ja) * | 1993-12-17 | 1997-06-30 | ザ、プロクター、エンド、ギャンブル、カンパニー | α−2−アドレノセプター作動剤として有用な6−(2−イミダゾリニルアミノ)キノキサリン化合物 |
AU677513B2 (en) * | 1994-02-08 | 1997-04-24 | Alcon Laboratories, Inc. | Novel process for preparation of clonidine derivatives |
WO1996004270A1 (en) | 1994-08-04 | 1996-02-15 | Synaptic Pharmaceutical Corporation | Novel benzimidazole derivatives |
US6087361A (en) * | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
EP2113246B1 (de) * | 2003-08-07 | 2016-06-22 | Allergan, Inc. | Zusammensetzungen zur Abgabe von Therapeutika in die Augen und Verfahren zu ihrer Herstellung und Verwendung |
AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
WO2009023752A1 (en) * | 2007-08-15 | 2009-02-19 | Allergan, Inc. | Adrenergic compounds |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US8293742B2 (en) * | 2008-08-01 | 2012-10-23 | Alpha Synergy Development, Inc. | Preferential vasoconstriction compositions and methods of use |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
EP2329849B1 (de) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
JP5747391B2 (ja) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 紅斑の安全かつ有効な治療のための改善された方法および組成物 |
AU2011231544B2 (en) | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
JP2013540143A (ja) | 2010-10-21 | 2013-10-31 | ガルデルマ・ソシエテ・アノニム | ブリモニジンゲル組成物及び使用方法 |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
US4908387A (en) * | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
-
1989
- 1989-10-12 US US07/420,817 patent/US5077292A/en not_active Expired - Lifetime
-
1990
- 1990-09-12 CA CA002025212A patent/CA2025212C/en not_active Expired - Fee Related
- 1990-10-09 AU AU63900/90A patent/AU628666B2/en not_active Ceased
- 1990-10-09 AT AT9090311021T patent/ATE104973T1/de not_active IP Right Cessation
- 1990-10-09 DE DE69008472T patent/DE69008472T2/de not_active Expired - Fee Related
- 1990-10-09 EP EP90311021A patent/EP0422878B1/de not_active Expired - Lifetime
- 1990-10-09 ES ES90311021T patent/ES2063289T3/es not_active Expired - Lifetime
- 1990-10-09 DK DK90311021.1T patent/DK0422878T3/da active
- 1990-10-11 IE IE363990A patent/IE65784B1/en not_active IP Right Cessation
- 1990-10-12 JP JP2275119A patent/JP2971118B2/ja not_active Expired - Fee Related
-
1991
- 1991-02-08 WO PCT/US1991/000894 patent/WO1992013855A1/en active Search and Examination
-
1992
- 1992-12-22 US US07/995,218 patent/US5300504A/en not_active Expired - Fee Related
-
1998
- 1998-04-22 HK HK98103362A patent/HK1004266A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2025212A1 (en) | 1991-04-13 |
JP2971118B2 (ja) | 1999-11-02 |
IE903639A1 (en) | 1991-04-24 |
JPH03145490A (ja) | 1991-06-20 |
EP0422878A1 (de) | 1991-04-17 |
AU6390090A (en) | 1991-04-18 |
DE69008472T2 (de) | 1994-09-15 |
US5077292A (en) | 1991-12-31 |
AU628666B2 (en) | 1992-09-17 |
EP0422878B1 (de) | 1994-04-27 |
HK1004266A1 (en) | 1998-11-20 |
CA2025212C (en) | 2000-07-04 |
DK0422878T3 (da) | 1994-09-05 |
IE65784B1 (en) | 1995-11-15 |
WO1992013855A1 (en) | 1992-08-20 |
DE69008472D1 (de) | 1994-06-01 |
ES2063289T3 (es) | 1995-01-01 |
US5300504A (en) | 1994-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE104973T1 (de) | (2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren. | |
EP0549594A4 (de) | (2-imidazolin-2-ylamino)chinoxalinderivate und methoden in ihrer anwendung. | |
CA2173974A1 (en) | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | |
IL96083A (en) | Pharmaceutical compositions comprising (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | |
YU85001A (sh) | Derivati 5-fenil-pirimidina | |
MA23639A1 (fr) | Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes. | |
ATE156119T1 (de) | 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel | |
CA2127542A1 (en) | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | |
ES8605507A1 (es) | Un compuesto de 3-indolcarboxamida | |
NO923413L (no) | Terapeutiske benzazepin-forbindelser | |
FR2666741B1 (fr) | Composition therapeutique pour inhiber l'agregation plaquettaire. | |
GR3020292T3 (en) | Use of 2-iminothiazolidin-4-one derivatives as new medicaments | |
RU93005181A (ru) | Производные (2-имидазолин-2-иламино)хиноксалина, лекарственная композиция и способ лечения | |
PT97005A (pt) | Processo de prparacao de (2-imidazolin-2-ilamino)tetra-hidroquinoxalinas e de composicoes farmaceuticas que as contem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |